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Neurocysticercosis (NCC) is an infection
of the central nervous system caused by
the larval form of the tapeworm Taenia
solium. Infections occur following the
accidental ingestion of tapeworm ova
found in human feces. NCC is a major
cause of epilepsy and disability in many of
the world’s poorer countries where fami-
lies raise free-roaming pigs that are able to
ingest human feces. It is frequently
diagnosed in immigrant populations in
the United States and Canada, reflecting
the high endemicity of the infection in
their countries of origin [1]. Although
parenchymal cysts are the most common
location in the brain and cause seizures,
cysts may also be present in the ventricles,
meninges, spinal cord, eye, and subarach-
noid spaces. Involvement in these other
sites may result in aberrant growth
(racemose cysts) and complicated disease
that is difficult to treat and may cause
increased morbidity and mortality.
Until recently, NCC and echinococcosis
were referred to as ‘‘neglected’’ diseases,
but are now recognized by the World
Health Organization (WHO) as ‘‘major
neglected diseases’’ [2]. In many endemic
communities, NCC is the cause of epilepsy
in $1% of the population. Here, we
provide an update of the importance of
NCC, recent epidemiological observa-
tions, and an outline of the goals of a
recently formed group of physicians, the
North American Neurocysticercosis Clin-
ical Research Consortium (NACC).
NCC is difficult to identify and treat.
Diagnosis requires brain imaging, a tech-
nology commonly unavailable in resource-
poor areas, and clinical diagnosis is
unreliable, as the manifestations are di-
verse and non-specific. Additionally, treat-
ment commonly involves weeks to months
of medication with close monitoring for
side effects and serial brain imaging. NCC
is a significant health problem in Latin
American countries (LAC), Haiti, sub-
Saharan Africa (SSA), India, Southeast
Asia, China, Indonesia, and other regions
less well categorized, such as New Guinea
and Eastern Europe [2]. Although accu-
rate estimates of the extent of infection
and disease are not available for most
endemic regions, many studies suggest a
higher prevalence of infection and disease
burden than has been appreciated by
experts [3,4].
Conventional diagnosis of NCC re-
quires a compatible clinical history, posi-
tive serology, and typical computed to-
mography (CT) or magnetic resonance
imaging (MRI) [5]. Determination of the
prevalence of infection is hampered by
variable sensitivity and specificity of each
of the diagnostic tests, which identify a
limited or overlapping proportion of the
‘‘true’’ prevalence of infection. For in-
stance, the sensitivity of the serum electro-
immunotransfer blot decreases dramati-
cally in those with calcified disease or a
single parenchymal cyst [6] and may be
falsely positive in persons exposed but not
infected.
Better estimates of infection can be
obtained by imaging of the brain to ensure
inclusion of individuals with NCC infec-
tion who are asymptomatic and seroneg-
ative to T. solium (see Box 1). One study in
Peru that characterized prevalence of
infection and NCC using a combination
of CT imaging, positive serology, and
history of seizures to identify infections [7]
reported an NCC seroprevalence of 24%.
An additional 13% of those with negative
serology had CT scans demonstrating
calcifications typical of NCC. Adding the
observed proportion of seropositive indi-
viduals to seronegative individuals with
CT imaging evidence of NCC yields an
overall prevalence of cysticercosis of 37%.
Even this substantial proportion of infec-
tion likely underestimates its prevalence in
this population. Applying similar calcula-
tions to earlier comparable studies per-
formed in Ecuador [8], Honduras [9], and
Mexico [10] yields prevalence estimates of
infection of 23%, 38%, and 15%, respec-
tively. Therefore, estimates of prevalence
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and 38%. Applying these prevalence
calculations to the 75 million persons at
risk in LAC found in 1993 [11] we
estimate between 11 and 29 million
persons have cysticercosis in LAC. Thus,
the burden of infection with cysticercosis
and NCC is substantial, and likely higher
in absolute numbers with the increasing
population currently at risk. These num-
bers also allow a more appropriate com-
parison between prevalence estimates of
other common infections in LAC [3].
Our estimate of the prevalence of NCC
in LAC is substantially higher than that
suggested by Bern et al. [11], which
estimated symptomatic NCC only, using
fairly conservative assumptions. An esti-
mate of mostly active epilepsy was deter-
mined by Bern et al. by subtracting the
epilepsy rates in non-endemic regions
from rates in endemic regions in Peru
[11]. Extrapolating to the 1993 population
at risk and adjusting for disease other than
seizures, the authors calculated that
400,000 individuals in LAC had symp-
tomatic NCC. More recent studies using
direct determinations of active epilepsy
due to NCC from active epilepsy rates
ranging from 0.6% to 1.8% suggest that
between 450,000 and 1.35 million persons
suffer from epilepsy due to NCC in LAC
(Table 1).
Similar to Latin America, many areas of
Asia are endemic for NCC. Studies in
endemic regions of India reveal high
burdens of infection and symptomatic
NCC [2]. In a community study in
southern India, the seroprevalence of T.
solium infection was 15.9%, active epilepsy
was present in 3.83/1,000 persons, and
28.4% of these individuals had NCC
detected by CT imaging. Extrapolating
these figures to the overall population in
India suggests that approximately 1 mil-
lion cases of epilepsy are due to NCC [12].
Cysticercosis is also highly endemic in
southwest China. According to a recent
WHO report, the average prevalence of T.
solium infection in China was 0.11%
(range, 0.05%–15%); the estimated num-
ber of patients with taeniasis was 1.26
million; and the estimated number of
cysticercosis cases was 3–6 million [2].
Although SSA is among the least
studied regions, accumulating evidence
suggests highly endemic transmission with
significant symptomatic disease. High
prevalence in pigs in many areas suggests
a high level of human taeniasis [13,14].
Serologic studies suggest many regions of
SSA have endemic infection that likely
affects large proportions of the population
(Table 2 - adapted from Winkler et al. [4]).
Epilepsy prevalence in SSA ranges from
5.2 to 74.4 per 1,000 persons. A recent
systematic analysis of the proportion of
epilepsy endemic regions due to NCC was
estimated at 29% (95% CI: 22.9–35.5)
[15]. Using this figure, the prevalence of
seizures due to NCC in SSA would be
1.7–24.8 per 1,000 persons.
ReportsofNCC inthe United States and
Canada have also been increasing over the
past 50 years, and these reports mostly
reflect disease in Hispanic immigrants
[1,16–18]. Regional estimates in the gener-
al population range from 0.2 to 0.6 per
100,000 in Oregon and Los Angeles
[18,19]. Of those presenting to urban
emergency departments because of sei-
zures, 2.1% were attributable to NCC
[18], similar to the proportion of seizure
patients with NCC (2%) in Houston [16].
This population also presents with compli-
cated subarachnoid disease, or racemose
cysticercosis, which is characterized by cysts
that proliferate, enlarge, and develop mem-
branes in the subarachnoid spaces of the
brain, mostly involving the basilar cisterns
and spine. Sequelae include hydrocephalus,
arachnoiditis, infarction, and entrapment
syndromes requiring long-term corticoste-
roids, anthelminthics, and serial imaging.
These individuals are frequently referred to
tertiary care centers where they may be
under the care of NACC participants.
Recognizing the importance of NCC in
immigrant communities from endemic
regions in North America, a group of
infectious disease and travel medicine
practitioners have come together to focus
efforts on management of NCC. The goals
of the NACC are to disseminate informa-
tion regarding diagnosis and treatment of
NCC, highlight areas of research need,
and advance knowledge through retro-
spective and prospective collaborative
studies of treatment for the more compli-
cated forms of NCC. Initially, we are
developing standardized methods to eval-
uate neuroimaging and morbidity and
hope to develop guidelines for treatment.
Box 1. Terms Used in This Manuscript
Infection: Any or all of the following: Evidence of prior ingestion of T. solium ova
resulting in aborted development and positive antibody response, presence of
viable or degenerated dead T. solium cysts anywhere in the body irrespective of
antibody response. Includes a positive serology for antibodies or antigen,
calcifications in brain or muscle, or viable or degenerating parasites.
Seroprevalence: Usually a defined population testing positive for antibodies to
T. solium cysts. Less commonly positive for cestode antigen in serum.
Neurocysticercosis: Evidence of T. solium infection of the brain with or without
symptoms.
Table 1. Estimated Numbers of Persons Infected with Neurocysticercosis or Epilepsy due to Neurocysticercosis by Region.
Geographic Region Number Infected Number with NCC
a Number with Epilepsy due to NCC
a
Latin America 11–29 million 14.9 million 0.45–1.35 million
India - - 1 million
China 3–7 million - 0.3–0.7 million
b
Africa - - 0.31–4.6 million
c
aSee text for methods used to derive these estimates.
bAssumes that 10% of those seropositive to T. solium have epilepsy. (Extraction of data from manuscripts summarized in references [7,11,31]). Seizure rates in
populations seropositive to T. solium were greater than in seronegative populations by approximately 9.4% (range 1.7–31.3%). Therefore, we assumed 10% of seizures
were attributable to NCC in Chinese seropositive populations.
cAssuming 1/3 of the SSA population of 560 million at risk.
doi:10.1371/journal.pntd.0001500.t001
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studies of the prevalence and burden of
disease have recognized NCC as a major
cause of epilepsy in endemic regions and a
cause of complicated brain disease in
immigrant populations. Resources direct-
ed at defining high prevalence regions,
preventing infection, and treating epilepsy
and other complications, all achievable
with present technology, and would re-
duce the burden of this debilitating disease
worldwide.
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